On Jan. 6, 2025 Akeso, Inc. (9926.HK) ("Akeso" or the "Company") reported its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, taking place on January 13, 2025, in San Francisco, California (Press release, Akeso Biopharma, JAN 6, 2025, View Source [SID1234649483]). The company’s founder, chairwoman, president, and CEO, Dr. Michelle Xia will share the latest developments and plans for its globally leading programs, including ivonescimab (PD-1/VEGF bispecific antibody), cadonilimab (PD-1/CTLA-4 bispecific antibody), and ligufalimab (CD47 monoclonal antibody), as well as more cutting-edge multispecific antibody pipeline assets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Time：SF local time 2:15-2:55pm, Jan. 15, 2025